Clinical trial
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts…
NCT00200161 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00200161 |
|---|---|
| Title | Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma |
| Official title | A Randomized Phase II Trial of Concurrent Temozolomide and Radiotherapy Followed by Dose Dense Versus Metronomic Temozolomide and Maintenance Cis-Retinoic Acid for Patients With Newly Diagnosed Glioblastoma and Other Malignant Gliomas |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | Schering-Plough Industry Columbia University Dana-Farber Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma, Gliomas |
| Intervention type | Drug |
| Interventions | Temozolomide |
| Enrollment | 127 |
| Start date | Aug 9, 2005 |
| Primary completion | May 4, 2017 |
| Completion | May 4, 2017 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 7, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: